3D tissue-engineered model of Ewing's sarcoma  by Lamhamedi-Cherradi, Salah-Eddine et al.
Advanced Drug Delivery Reviews 79–80 (2014) 155–171
Contents lists available at ScienceDirect
Advanced Drug Delivery Reviews
j ourna l homepage: www.e lsev ie r .com/ locate /addr3D tissue-engineered model of Ewing's sarcoma☆Salah-Eddine Lamhamedi-Cherradi a, Marco Santoro a,b,c, Vandhana Ramammoorthy a, Brian A. Menegaz a,
Geoffrey Bartholomeusz d, Lakesla R. Iles d, Hesham M. Amin e, J. Andrew Livingston f,
Antonios G. Mikos b,c, Joseph A. Ludwig a,⁎
a Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77054, USA
b Department of Chemical and Biomolecular Engineering, Rice University, Houston, TX 77005, USA
c Department of Bioengineering, Rice University, Houston, TX 77005, USA
d Department of Experimental Therapeutic, SiRNA screen laboratory, (MDACC), Houston, TX 77005, USA
e Department of Hematopathology (MDACC), Houston, TX 77005, USA
f Division of Cancer Medicine (MDACC), Houston, TX 77005, USAAbbreviations: ESFT, Ewing's sarcoma family tumors; E
matrix; PDX, patient-derived tumor explants;MSC,mesen
1R, insulin like growth factor-1 receptor; mTOR, mamma
☆ This review is part of the Advanced Drug Delivery Revi
⁎ Corresponding author.
E-mail address: jaludwig@mdanderson.org (J.A. Ludw
http://dx.doi.org/10.1016/j.addr.2014.07.012
0169-409X/© 2014 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oAvailable online 7 August 2014Keywords:
Ewing's sarcoma
MCTS
3D
Tissue-engineering
Scaffolds
ECM
Tumor model
Preclinical testingDespite longstanding reliance upon monolayer culture for studying cancer cells, and numerous advantages from
both a practical and experimental standpoint, a growing body of evidence suggests that more complex three-
dimensional (3D)models are necessary to properlymimic many of the critical hallmarks associatedwith the on-
cogenesis, maintenance and spread of Ewing's sarcoma (ES), the second most common pediatric bone tumor.
And as clinicians increasingly turn to biologically-targeted therapies that exert their effects not only on the
tumor cells themselves, but also on the surrounding extracellularmatrix, it is especially important that preclinical
models evolve in parallel to reliably measure antineoplastic effects and possible mechanisms of de novo and ac-
quired drug resistance. Herein, we highlight a number of innovativemethods used to fabricate biomimetic ES tu-
mors, encompassing both the surrounding cellular milieu and the extracellular matrix (ECM), and suggest
potential applications to advance our understanding of ES biology, preclinical drug testing, and personalized
medicine.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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The Ewing's sarcoma family of tumors (ESFT) is an aggressive form of
childhood cancer that has historically included classic Ewing's sarcoma
(ES), Askin tumors, and peripheral primitive neuroectodermal tumors
(PNET) [1–6]. Though previously considered to be distinct clinical
entities, given subtle variation in their presenting sites and immuno-
phenotype, the World Health Organization now advocates a simpliﬁed
nomenclature using ES to represent the aforementioned tumors, as
they consistently have a round cell morphology, ubiquitously express
CD99, and harbor a near-universal pathognomonic chromosomal trans-
location—afﬁxing the N-terminal EWSR1 gene to a C-terminal ETS gene
[7–9]. Although rare in comparison to carcinomas, ES is the second
most common pediatric bone tumor, presenting in three cases per
million [10]. Racial and gender disparities exist; ES is nine times more
common in Caucasians than in African Americans and slightly more
prevalent in males than females with a 6:5 ratio [11,12].
Clinically, ES is an aggressive, rapidly fatal malignancy that can
develop in osseous and extraskeletal sites and naturally spreads to the
lung, bones, and bone marrow if not rapidly treated [11,13,14]. In fact,
even in the 60–70% of cases where a solitary site is visualized radio-
graphically, micrometastatic disease is presumed to exist within the
lung [15]. Fortunately, signiﬁcant strides in multimodality treatment
have enhanced the 5-year survival rate for those with localized tumors
from 10% in the pre-chemotherapy era (prior to 1962) to about 75%
today [16]. Yet, for inexplicable reasons, this progress in curing patients
suffering from localized disease has not extended to those with meta-
static or rapidly recurrent disease, and less than 30% of these patients
will survive.
In an effort to change that dismal outcome, extensive research has
deﬁned key oncogenic events responsible for the growth and mainte-
nance of ES. And not withstanding the lack of a conclusive cell of origin,
experimental evidence suggests that ES emanates from a single plurip-
otent bone marrow-derived mesenchymal stem cell (MSC) that has
neuroendocrine features and acquires a speciﬁc cancer-causing chro-
mosomal translocation of the EWSR1 gene [17–21]. EWSR1-FLI1,
which occurs in 85% of ES, results from the apposition of the N-terminal
portion of the EWS gene (located at 22q12) with the C-terminal FLI1
gene of the ETS transcription factor family [22–24]. Less common translo-
cations include EWS-ERG (5–8% of cases) [25] and EWSR1-ETV1 [26],
EWSR1-EIAF [27], and EWSR1-FEV [28], which each occurs in less than
1% of reported cases [24,29]. On rare occasions, FUS (one of the three
TET genes, also known as TLS) can occasionally substitute for EWSR1 to
produce a FUS-ERG positive ES [30] and non-ETS pairings with ZSG [31]
or NFATc2 [32] have also been reported—the biological and prognostic
signiﬁcance of these exceedingly rare chromosomal aberrations is
unknown.
While a number of innovative drugs in preclinical development are
aimed squarely at the tumorigenic EWS-FLI1 fusion protein, it has
been historically quite challenging to counteract this transcription
factor, given its inaccessibility within the cell nucleus. Thus, in addition
to conventional chemotherapies that clearly have a prominent role intreatment, most biologically targeted therapies used in the treatment
of ES either target downstream signaling cascades induced by EWS-
FLI1 activity (e.g., IGF1/IGF-1R, TGF-β, Hedgehog/GLI, Wnt/β-catenin,
and Notch/p53) or the surrounding tumor matrix upon which ES cells
rely [33–41]. Of particular relevance to the ﬁeld of tissue-engineering,
it is these latter targets and/or processes,which include the extracellular
matrix (ECM), nascent blood vessel formation [42,43], and cell migra-
tion ormetastasis thatwill be of greatest relevance since they are poorly
modeled by traditional monolayer culture techniques [44].
2Dmonolayer culture has, of course, been themainstay for culturing
cancer cells for at least ﬁve decades, and continues to be the predomi-
nant method for testing the antineoplastic drug candidates in the
preclinical setting given its many advantages over more complex
systems; 2D culture is readily performed using standardized methods,
promotes rapid cell growth, uses translucent material amenable to
monitoring cells in real-time using lightmicroscopy, requires no special
equipment, and is cost effective. Yet, as the cancer biology community
can attest, cells placed upon chemically inert ﬂat polystyrene tissue-
culture plates under conditions of high oxygen tension and abundant
glucose and nutrients poorly mimic how the cells would otherwise
behavewithin their native in vivo host [45]. As a direct result of this iat-
rogenic effect on cancer cells grown in the laboratory, it is not surprising
that the precise protein targets and/or signaling cascades being interro-
gated in high-throughput anti-cancer drug screens are profoundly
different from what occurs in patients and this, in part, explains why
the majority of biologically targeted therapies may succeed in the lab
but ultimately fail in the clinic. This holds true for traditional cytotoxic
chemotherapies as well, since most work by indiscriminately damaging
DNA in rapidly dividing cells that grow in monolayers at unparalleled
rates unheard of in even their fastest clinical counterparts. Thus, for all
the advantages of 2D cell culture for cancer research, if the information
gained is unreliable—or even worse, leads to expensive clinical trials
that provide false hope to patients—onemust reassesswhether this pre-
clinical approach is still appropriate when better options exist [46–49].
In recognition of the previously described shortfalls inherent in
monolayer culture, and ease with which ES cells/explants can be culti-
vated in immunocompromised mice, there has been a recent resur-
gence in the use of mouse models [50,51]. In part, this gradual
pendulum swings back toward tumor xenografts, which had favored
in vitro testing over the last several decades, is occurring in an attempt
to better mimic elements of the tumor microenvironment (e.g., tumor
associated stroma, growth factors, and abundant heterotypic cells).
Further, the use of low-passage number explants obtained directly
from patients—rather than from long-established cell lines—appears to
reduce phenotypic drift from corresponding human tumors and helps
to preserve surrounding tumor-associated architecture [52].
Despite the advantages of these so-called patient-derived tumor ex-
plants (PDX), they are not without their own challenges: (i) xenografts
can still behave differentlywhen placed into amurine host, especially in
subsequent generations of engraftment where mouse tissue has
replaced the human tumor-associated stroma; (ii) monitoring can be
difﬁcult, particularly for orthotopic locations; (iii) specialized surgical
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Additionally, because xenografts are placed into immunocompromised
mice devoid of a functioning human immune system, it is all but impos-
sible to use them to evaluate the growing list of immunomodulatory
drugs, such as checkpoint inhibitors, gaining increased utility in the
clinic. Last, PDXmodels are costly to generate since they require expen-
sive core-needle or open biopsies of human tumors and, subsequently,
incur substantial labor costs to perform drug testing.
Overall, challenges associated with current 2D and xenograft tumor
models have motivated researchers to develop innovative ex vivo 3D
cell culture systems that provide a more physiologically relevant cellu-
lar environment that meets the needs of the basic science and clinical
research community (Table 1) [53,54]. Prominent examples include
the culture of cells in relatively simple spheroids [55], pellet cultures
[56], or cell–matrix interactions (using protein gels or synthetic
polymer scaffolds) [57–59]. More complex 3D cancer models that rely
upon co-culture or hybrid culture systems have included encapsulated
protein gels seeded with multiple cell types [60], hybrid methods with
3D scaffolds layered upon 2D monolayers [61], and heterotypic cell
populations grown as tumor spheroids [62].
Many of the strategies developed originally for tissue-regenerative
purposes have recently been adapted for the purpose of modeling
human tumors in the preclinical setting, and the increased control of
tumor microenvironment has revealed signiﬁcant advantages over 2D
and xenograft culture. In fact, it is this ability for tissue-engineered sys-
tems to devolve complex microenvironmental themes (e.g., signaling
molecules, biomechanical forces, and metabolic factors) from poorly
controlled native/self-organizing cell aggregates that make their use
so appealing. As shown in Fig. 1, each component of a tumor's microen-
vironmental niche can be varied experimentally to determine the
relative impact on the cancer cell.
3D culture, for example, can be designed to resemble the in vivo
malignancy's shape and environment, which in turn, can inﬂuence the
behavior and gene expression of the cell, as has been demonstrated in
a colorectal cancer model [63]. Further, by manipulating not only the
3D architecture itself, but also the heterotypic cell composition, one
can selectively reintroduce key interactions between tumor cells and
surrounding stromal cells within an in vivo-like human tumormicroen-
vironment. By creating a more biomimetic 3D environment of cancer,
these 3D in vitro models provide important alternatives to both
2D culture and in vivo models by, (i) delivering the applicable matrix
constituents in a 3D conﬁguration found clinically, (ii) co-culturing can-
cer cells, endothelial cells and other stromal associated cells in spatiallyTable 1
Methods used for ex vivo culture of ES cells.
Patient PDX
B
Complexity Organism Xenograft
Substrate NA (Orthotopic/heterothopic)
Cell type NA Homotypic/heterotypic
Tumor niche Physiologic Chimeric:
animal/human
Biology studies Limited Yes
(costly)
Preclinical drug testing
(correlation with human trials)
NA High
(low throughput) (i
Biomarker development Yes Yes
Personalized medicine
(CLIA-certiﬁed)
Yes Yesadequatemanner, (iii) examining and adjustinghypoxia tomimic levels
found in native in vivo tumor environment and (iv) censoring the
release of angiogenic factors by cancer cells in response to hypoxia.
As we delve more deeply into the steady rise of tissue-engineered
tumors, and highlight both current applications and future directions
they may take in helping to advance our collective understanding of
tumor behavior, we take care to distinguish a cancer cell's innate behav-
ior to self-organize (i.e., to form spheroids and other cell aggregates)
from their capacity to form complex 3D relationships upon exogenous
non-biologically derived tissue-engineered substratum. Though this
review highlights the role of tissue-engineered models of ES, we
acknowledge the relatively rarity of this bone cancer and, therefore, sus-
pect the concepts presented herein will ﬁnd more broad spread utility
as they relate to other sarcoma subtypes or carcinomas that metastasize
to the bone or lung.
2. Tumor structures and ECM generation intrinsic to the cancer cells
2.1. Tumor spheroids
Multicellular tumor spheroids (MCTS) are spherical aggregates of
tumor cells that autonomously form when cultured in non-adherent
substrates that are devoid of requisite ECM or growth factors. Since
their discovery, MCTS have been demonstrated to more closely resem-
ble the phenotypic behavior of human tumor tissues and, for that rea-
son, have been used extensively to model key elements of malignant
tumor behavior [64]. Among numerous examples, they have proven
useful to study avascular tumor growth, intracellular tumor hypoxia,
and the effects of cell-ECM communication upon drug sensitivity.With-
in this subsection, we discuss common methods of spheroid formation,
highlight their phenotypic resemblance to human tumors, and describe
real-world applications that are helping to decipher the complex
biology of ES and cancer more broadly.
Since Inch et al. ﬁrst described the formation of nodular carcinoma
MCTS in 1970 using the spinner ﬂask method, the number of methods
capable of yielding MCTS has grown signiﬁcantly and generally fall
into two broad categories [65,66]. Theﬁrst group relies upon equipment
that induces turbulence into the cell culture medium and, thereby, pre-
vents cells from adhering to solid surfaces. In contrast, the second group
achieves a similar effect simply by altering the extracellular environ-
ment to make it incompatible with cell-ECM adhesion. Prominent
examples of the former ‘mechanical’ group include the original spinner
ﬂask and rotary wall vessel reactors (Fig. 2A), which suspend cells3D 2D
ioengineered 3D scaffolds MCTS
Organ/tissue Multicellular aggregate Cellular
Synthetic ﬁbers
(e.g. PCL)
Biological gels (e.g. matrigel,
collagen, laminin rich gels)
Plastic or glass
Homotypic/heterotypic Homotypic/heterotypic Homotypic
Yes Limited No
Yes
(specialized techniques)
Limited No
Intermediate
ntermediate throughput)
Intermediate
(high throughput)
Low
(high throughput)
Unknown No No
No No No
A B
Fig. 1. (A) Principal components of the tumor microenvironment that affect cell behavior. Signaling factors include ECM, GFs, etc. Biomechanical forces include 3D architecture and me-
chanical loading. Hypoxia, pH, nutrients and stress affectmalignant cell phenotype. (B) Key cell effectors in tumormicroenvironment. Abbreviations: GF, growth factor; ECM, extracellular
matrix;MMPs, metalloproteinases; IGF-1, insulin growth factor 1; IGF-1R, insulin growth factor 1-receptor; FAD, focal adhesion kinase; PI3K, phosphatidylinositide 3-kinases; ATP, Aden-
osine triphosphate;mTOR, mammalian target of rapamycin; NHE-Flux, sodium-proton exchanger; HIF-1, hypoxia inducible actor-1; ROS, reactive oxygen species; and ICAM, intercellular
adhesion molecule 1.
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gravity [53,67]. Whereas the latter ‘intrinsically non-adherent group’
places cell suspensions onto non-adherent micro-etched nano-culture
plates (NCP) (Fig. 2B) or agarose coated Petri dishes (Fig. 2C) that pre-
vent cell binding. Newer production techniques include hanging drops
(Fig. 2D) [68,69] and microﬂuidic chips [70], which can produce more
uniform spheroid size at the risk of being more specialized and difﬁcult
to master.
Regardless of the chosen method to produce them, MCTS evolve
from disorganized cell aggregates in the ﬁrst week into highly symmet-
ric spherical structures by two weeks that have distinct zones: (i) a
central core of necrotic cells or ones undergoing apoptosis, (ii) an
inner layer of non-proliferating quiescent cells, and (iii) an outer
nutrient-rich layer of proliferating cells capable of interacting, albeit in
a limited fashion, with surrounding ECM [55,64]. Though subtle cell-
type dependent differences in morphology exist, ranging from simple
spheroids uniformly coated in ECM to more intricate structures thatA
B
C D
Fig. 2.Multicellular tumor spheroids (MCTS) in vitro production techniques of ES. (A) Spinner
derived 3Dmatrices cultures. (D) ES hanging-drop cultures. (D1) ES cell line counting using Bec
plated on the lid of a Greiner 96-well plate. (D3) The lid was placed back on the 96-well plat
incubator for 72 h. (D4) The lids were removed and 300 μL of RPMI was added to a Nano-C
incubate for 1 h and remove 100 μL. (D5) Spheroids were imaged using the GE InCell Analyzerhave glandular structures resembling ductal tissues, as a class MCTS
appear to bettermimic human tumors than 2Dmonolayerswith respect
to proteomic and genomic expression proﬁles [71–79]. Lawlor et al., for
example, have noted that growth rates, cell morphology, cell–cell
junctions, and kinase activation of ES spheroids closely mimic those
of primary Ewing tumors [80]. Further, given their contrasts in pH,
oxygen tension, and proliferative rates that exist between the inner
and outer layers, MCTS can be used to determine layer-dependent anti-
neoplastic effects that couldn't otherwise be observed using traditional
monolayers [55,81–85].
As such, ES spheroids have been used extensively to judge the effec-
tiveness of chemotherapeutic and biologically targeted drugs (Fig. 3)
[53,67,80,86,87], to study the impact of cell signaling pathways that reg-
ulate ES cell proliferation [53,80,88], to investigate the effects of tumor
architecture upon immune cell function, and to identify suitable
antigens for immunotherapeutic strategies [89,90]. ES MCTS have also
proven useful for modeling micrometastatic disease, contributed toﬂask spheroid cultures. (B) Micro-etched nano-cultures. (C) Biologically (e.g. collagen gel)
kman Coulter Vi-Cell XR Cell Viability Analyzer. (D2) 20 μL of cell suspension (100 ES cells)
e containing 100 μL of RPMI (cell culture complete medium) and carefully placed in the
ulture® Plate (Scivax NCP-LS) to allow the drop to come in contact with the media, re-
6000. (D6) Images of ES spheroids cells at 2 × 104 cells/mL and 5 × 104 cells/mL.
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ECM contact) [53,88], and served as a platform to evaluate heterotypic
interactions between tumor cells and vascular progenitor cells
responsible for angiogenesis [77].
2.2. Tumor organoids
Though MCTS grown in nonadherent conditions can reproduce
some features of human tissues and/or tumors (e.g. oxygen and drug
diffusional gradients, cell–cell contact, etc.) their spherical self-
organized structure cannot be said to truly mimic the more complex
patterns observed in vivo. Surprisingly, a ﬂurry of research reports pub-
lished since 2013 have revealed an enormous untapped potential for
noncancerous human embryonic pluripotent stem cells (PSC) and/or
induced pluripotent stem cells (iPSC) to self-organize into lab-grown
organ-like structures (i.e. organoids) when coaxed to do so by external
spatiotemporal perturbation using nutrients, growth factors, or rarely
heterotopic cells. Prominent examples include ex vivomodels of embry-
onic human brain [91], functional liver buds that resemble the human
liver [92], and ureteric buds that differentiated toward the renal
collecting system (Table 2) [93]. Additionally, a lung organoid has
been described that forms beneath the renal capsule of mice in vivo
[94]. That human PSCs intrinsically retain the capacity to self-assemble
into spatially-complex higher-ordered organ-like structures ex vivo is
truly amazing and suggests the genomic or epigenetic information
contained within the PSCs is enough to drive organ-level differentiation
if augmented by the ‘correct’ microenvironmental cues.
While the referenced organoidmodels could revolutionize the tissue
engineering and regenerative medicine ﬁelds by restoring or replacing
diseased organs, we foresee novel opportunities to use organoids to
study bidirectional regulatory feedback that exists between tumors
and their supporting microenvironmental ECM. Among just a few of
the examples, one could imagine an ex vivo study of organ-speciﬁc ma-
lignancies (i.e. brain cancer, colon cancer, etc.) using surrogate
organoids that have been corrupted by site directed mutagenesis or
less-speciﬁc radiation-induced genomic damage to produce tumors.
Resulting 3D tissue/tumor hybrids could then be used to screen promis-
ing drug candidates, to study metastasis to and from the organoid, and
to determine stromal growth factors necessary for tumor maintenance.
2.3. Biologically derived 3D substrates
Despite the advantage spheroids and organoids have over their 2D
counterparts, it can be challenging to model their interaction withA
Fig. 3. Chemotherapeutic and biologically targeted drug sensitivity testing ES monolayers and
therapeutic and biologically targeted drugs. Cell viability data are shown. (A) Response to dox
human IGF-1R (Roche).surrounding ECM, as most are devoid of supporting cells (endothelial
cells, ﬁbroblasts, etc.) or soluble growth factors. In an attempt to
overcome those limitations, 3D models of ES have integrated naturally
occurring substrates derived from human tumors, elements of the base-
ment membrane, and/or gels rich in collagen or laminin [21,95–98]. By
adding back key elements of the surrounding ECM, one can also invoke
membrane-bound integrin signaling and, thereby, activate a diverse
array of downstream signaling cascades including those responsible
for angiogenesis [95,96,99], cancer cell motility [97,100], and drug
sensitivity [101,102].
Of thosementioned above, collagen-supplemented 3Dmatrices pre-
dominate and have been used extensively in severalmodels ofmetasta-
sis and cancer cell migration that require interaction between cancer
cells and physiological cross-linked networks of collagen [103–107].
Collagen 3D matrices can be reproducibly manufactured and modiﬁed
by a number of factors including their source, crosslinking chemistry,
pH, temperature, and monomer concentration without affecting their
microstructure. However, minor changes in these factors can signiﬁ-
cantly alter the resulting matrices and lead to inconsistent results
from one laboratory to the next. To minimize these environmental var-
iations and reduce one's reliance upon ill-deﬁned biological derivatives
that can lead to irreproducible results, an attractive alternative is to
fabricate the tumor niche directly [108].3. Engineering the tumor niche
The tumor niche, i.e. local microenvironment composed of stromal
cells and ECM, plays a well-recognized role in cancer development
[109–111]. And just as the niche can inﬂuence malignant cells, tumor
cells can alter the physical, biochemical, and biomechanical properties
of their surroundings to reinforce their malignant phenotype
[112–117]. The resulting dysregulated ECM can promote cancer pro-
gression by facilitating malignant transformation, local tissue invasion,
and subsequent metastasis [118]. Additionally, tumor-induced anoma-
lies in the ECM can alter the behavior of stromal cells and lead to
angiogenesis and inﬂammation that generates a tumorigenic microen-
vironment [119–135]. An in-depth understanding of the dynamic inter-
play between a tumor and the nichewas found to be critical in the effort
to develop innovative antineoplastic therapies that act upon the tumor
niche and deprive tumors of oncogenic stimuli.
As amethod to delineate themost important interactions between a
cancer and its tumor-associated microenvironment, particularly ones
that profoundly inﬂuence a cancer cell's response to biologically
targeted therapy, our laboratory has adapted methods normallyB
spheroids. ES were cultured as both monolayers and spheroids in the presence of chemo-
orubicin (CID: 31703) (B) Response to fully humanized monoclonal antibody R1507 anti-
Table 2
Organoids used to study normal physiology and diseases.
Organoid type
(organ)
Disease modeling Cell type Scaffold type Bioreactor Growth factor/nutrients Reference/journal
Brain Microcephaly hESC, hPSC, Matrigel Spinning hbFGF, RA Naturea
Liver Cirrhosis iPSC-LB, iPSC-Hes, HUVECs, hMSC Matrigel/collagen IV NA hbFGF, hBMP4, HGF, oncostatin-M Natureb
Kidney Polycystic kidney hESC, iPSC Matrigel coated plate NA BMP4, FGF2, RA, activin A, BMP2 Nature Cell Biologyc
Eye (retinal) Degenerative
diseases
hESC, hiPSC Laminin coated dishes NA BMP4, WNT3a PNASd
Intestinal Gut defects, IBD,
transplantation,
hESC, iPSC, Matrigel NA FGF4, WNT3a, activin A, R-spondin-1,
noggin, EGF
Naturee
Colon rectal cancer Colorectal tumor cells Collagen coated dishes NA EGF, bFGF Gastroenterologyf
Lung Lung cancer AEC, E14.5 lung single-cell suspension In vivo kidney capsule NA NA JCIg
Abbreviations: IBD, inﬂammatory bowel disease; hESC, human embryonic stem cells; hPSC, human pluripotent stem cells; iPSC-LB, induced pluripotent stem cells-liver buds; iPSC-Hes,
induced pluripotent stem cells-hepatic endoderm cells, HUVECs, human umbilical vein endothelial cells; hMSCs, humanmesenchymal stem cells; hbFGF, human basic ﬁbroblast growth
factor, hBMP4, human bone morphogenetic protein 4; HGF, human growth factor; FGF2, ﬁbroblast growth factor 2; RA, retinoic acid; BMP2, Bone morphogenetic protein 2; Wnt3a,
wingless-type MMTV integration site family member 3A; FGF4, ﬁbroblast growth factor 4; EGF, endothelial growth factor; and AEC, alveolar epithelial cells.
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a Lancaster MA & al. Nature. 501, 373–379 (2013).
b Takebe T & al. Nature. 499, 481–499 (2013).
c Xia Y & al. Nature Cell biology. 15, 1507–1516 (2013).
d Meyer JS & al. PNAS. 106, 16698–16703 (2009).
e Spence JR et al. Nature. 470, 105–108 (2011).
f Sato T & al. Gastroenterology. 141, 1762–1772 (2011).
g Chapman et al. JCI. 121, 2855–2862 (2011).
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simple transfer of ES cells from a monolayer to 3D scaffold resulted in
striking changes in ES cell morphology, behavior, growth kinetics, and
sensitivity to antineoplastic drugs. Though we have taken just the ﬁrst
few steps to understand how the tissue-engineered scaffolds achieved
those profound effects, we anticipate a tissue-engineered bone tumor
niche will better mimic human ES tumors [136–139] and retain many
of the advantages inherent in ex vivo preclinical cancer models.
3.1. Tissue-engineered 3D scaffolds
As applied to oncology research, the main purpose of tissue-
engineered 3D scaffolds is to recapitulate essential architectural,
mechanical, and biochemical elements of the tumor microenvironment
in a way that promotes tumor cells to behave as they naturally would if
present within a human tumor [140–144]. Also, the tissue-engineered
3D scaffolds should support physiological exchange of nutrients,
oxygen, and metabolic waste byproducts, and ideally be compatible
with standard experimental techniques (e.g.microscopy, immunohisto-
chemistry, cell proliferation assays).While no scaffoldmaterial achieves
all of those traits, several have proven useful for oncology research
[145].
Deﬁned generically as three-dimensional solid or porous biomate-
rials conducive for cell growth, the scaffolds can be native or synthetic,
permanent or biodegradable, and can vary by other traits, such as poros-
ity or surface functionality that inﬂuence their appropriateness for spe-
ciﬁc preclinical models (Table 3). Moreover, the methods used for
ﬁbrous scaffold fabrication can also determine the level of control scien-
tists have over scaffold architecture, with more disordered weaving,
knitting, braiding, and electrospinning techniques on one end of the
spectrum (deﬁned in Table 4), and well-ordered computer controlled
3D-printed scaffolds on the other. Though less common, scaffolds
intended for implantation into animal models must also be safe to the
host and biocompatible with the site in which it is inserted. Though a
comprehensive discussion of the myriad scaffolds types is beyond the
scope of this publication, several reviews cover this topic extensively
[146,147].
Naturally, given this wide assortment of scaffold options, several
have proven value in culturing malignant tumors. This includes
poly(ε-caprolactone) (PCL), polylactide (PLA), polyglycolide (PGA),and co-polymers (PLGA: poly lactic-co-glycolic acid), which are biode-
gradable and able to form various structures such as ﬁbers, mesh, and
sponges (Table 5) [148,149]. Cancer cell lines have been shown to
adhere and grow on these synthetic scaffolds and appear capable of
forming 3D structures that are morphologically and histologically simi-
lar to in vivo tumors [54,150–152]. Our own laboratory has employed
electrospun PCL as the preferred biomaterial to model the bone niche
and found it useful to study ES cell growth kinetics, drug sensitivity,
and mechanisms of acquired drug resistance [54]. In our hands, cells
attached to the PCL ﬁbers and proliferated throughout the uppermost
portion of the scaffolds, reaching a maximum cell number of about
300,000 cells/scaffold and depth of 150 μm.
Although the parameters we selected to culture ES within PCL scaf-
folds would almost certainly need to be adapted if used to model
other sarcoma subtypes, this study provides proof of concept that ES
cells can attach and grow on unmodiﬁed microﬁber scaffolds that lack
ancillary bioactive moieties (Fig. 4). It also brings to light several com-
mon ﬁndings we have encountered when growing osteosarcoma and
ES cells within 3D PCL scaffolds. First, when grown in static culture ES
cells eventually reach a maximal cell number and depth of penetration,
with preferential growth in the uppermost section that is well oxygen-
ated and more accessible to nutrients [153–158]. Under static condi-
tions, oxygen and nutrient levels drop dramatically as distance from
the scaffold surface increases, and viable cell growth is often limited
to only about 200 μm [159,160]. After micropipetting ES cells onto
3D PCL scaffolds, they start to proliferate and eventually migrate
throughout this oxygenated zone until a maximum density is reached.
More deeply seeded cells within the scaffold will be under metabolic
stress and exhibit slower proliferation rates.
As cell number and ECM deposition increase, uneven distribution of
nutrients, oxygen, andmetabolicwaste by-products can emerge even in
the uppermost 200 μm of the scaffolds. This, in turn, promotes cell apo-
ptosis/death within unfavorable pockets within the scaffold—a problem
exacerbated by the high metabolic demands of cancer cells [161–163].
As previously reported, diffusion gradients within tumor spheroids
have been shown to produce this type of varied cell structure and are
widely used to study the growth kinetics and hypoxic effects of tumor
cells present within avascular tumor micro-regions within irregular
tumor vasculature [72,164,165]. When grown under static growth con-
ditions, ES impregnated PCL scaffolds could, therefore, equally serve to
Table 3
Methods, factors and biomedical application of scaffolds.
Method Examples Polymers Properties Application
Biodegradable porous scaffold:
polymeric porous scaffolds with
homogenous network
Casting, leaching and foaming
methods
PLLA, PLGA, PDLLA, collagen, etc. Controlled structure & production Drug delivery, bone &
cartilage tissue engineering
Fibrous scaffolds: mimicking the
architecture of natural human tissue
at the nanometer scale (Nano,
micro & nonwoven ﬁber)
Electrospinning, self-assembly,
& phase separation
PCL, PGA, PLA, PLGA Biomechanical and biocompatible
high surface area
Tissue engineering, drug
delivery & wound healing
Hydrogel scaffold: shape-retentive
polymeric network swollen with a
high percentage of water
Microﬂuidics, micromolding,
photolithography, &
emulsiﬁcation
PGS, PEG, PDMS, & Silicon
PMMA, HA, PEG, Alginate
PMMA, PAA, Fibronectin,
chitosan
Collagen, gelatin & HA
Biological, mechanical, & physical
complexity of structure, shape &
size
Microdevices, biochips,
cell-based microreactors,
etc.
Microsphere scaffold: prepared from a
large variety of biodegradable
materials, enabling easy control of
porosity and pore interconnection
Thermal induction
Particle aggregation
Solvent evaporation
Freezing & drying
PEG, PLLA
Chitosan, HAP
PLGA & PLAGA
Collagen, PLGA, Chitosan
Highly porous for cell transplant
Mechanical stability
High cellular density
Durable & ﬂexible structure
Bone tissue engineering
Ceramic scaffold: useful due to their
similarity to bone mineral & their
osteo-conductivity and
biocompatibility
Sponge replication calcium
phosphate coating
TCP, BCP, PU sponge, calcium
phosphate, PLGA, PS, PP,
collagens, silk and hair ﬁbers,
etc.
Enhanced biocompatibility and
bioreactivity
Bone tissue engineering &
orthopedic application
Functional scaffold: delivering of
substances inducing cell growth
Growth factors, hormones
and ligands release
Alginate, gelatin, collagens,
ﬁbrin, PLGA, PLA, etc.
Variable structure: hydrogels,
membranes, microspheres, foams
& membranes
Endothelium interaction,
tumor vascular interactions,
bone regeneration & wound
healing
Acellular scaffold: elimination of the
cellular composition without affecting
the composition, mechanical integrity
and biological activities of the
remained ECM
Decellularisation Biological organs (e.g. lung) Retain biomechanical properties,
anatomical structure & native ECM
Tissue engineering
“Tissue scaffold”: assist in the production
of ECM, and possible integration with
in vivo tissue growth
Robotic & automated deposition
of cells in 3D space
Tubular collagen gel Sodium
alginate
Layers deposition of ECM or cells
Multicellular composition
reconstituting tissues
Printing 3D organs, acellular
polymeric scaffolds &
biochips development
Abbreviations: PLLA, polylactide; PLGA, poly lactic-co-glycolic acid; PDLLA, poly-D,L-lactide; PCL, Polycaprolactone; PGA, polyglycolide; PLA, polylactide; PGS, poly glycerol-sebacate; PEG,
Poly ethylene glycol; PDMS, Polydimethylsiloxane; PMMA, polymethyl methacrylate; HA, hyaluronic acid; PAA, Poly acrylic acid; PLAGA, poly-lactide-co-glycolide; TCP, Tricalcium phos-
phate; BCP, Biphasic Calcium Phosphate; PU, Polyurethane; PS, Polystyrene; and PP, Polypropylene.
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tumors.
A second notable ﬁnding in our scaffold-based model of ES was that
cell proliferation within PCL scaffolds more closely approximated theTable 4
Fibrous scaffold fabrication methods.
Method Deﬁnition
Electrospinning Fibers are drawn under an applied electric
ﬁeld and deposited on a surface forming
a ﬁbrous scaffold
Knitting Fibers are connected in series of loops
Braiding Fibers are braided by intertwining
three or more ﬁber strands
Weaving Fibers are weaved by interlacing warp
and weft ﬁbers in perpendicular directionsgrowth kinetics of human tumor xenografts, which were both signiﬁ-
cantly less thanmonolayer cultures [54]. As expected, since themajority
of cytotoxic chemotherapies act in common upon cells undergoing
DNA synthesis or cell division (i.e., actively progressing through
the cell cycle), the faster mean doubling time of ES cells cultured
as monolayers (24 h) tends to overstate the true clinical activity
later determined if/when a drug reaches the clinic [166]. Thus, if
for no other reason than accurately modeling antineoplastic activity
in the preclinical setting, scaffold-based cell culture appears to be
advantageous over monolayer-based options [167].
In actuality, however, scaffold culture not only affects the prolifera-
tive rate but also profoundly impacts the ES morphology, internal sig-
naling patterns, and oftentimes the response to biologically targeted
therapies that have become increasingly common for the treatment of
all cancer types. Illustrating this fact, our laboratory conﬁrmed that ES
cells acquire an in vivo-like round cell morphology when they are
placedwithin PCL scaffolds and continue to express immunohistochem-
ical biomarkers normally expressed by human ES tumors (CD99+, IGF-
1R+, keratin−, and SMA−) [54]. Though more extensive testing is re-
quired in other pathways, the proteomic expression proﬁles along the
IGF-1R/PI3K/mTOR signaling pathway, as measured by Western blot-
ting and ﬂow cytometry, would suggest that 3D PCL scaffolds and mu-
rine xenografts can reliably mimic critical signaling cascades of known
importance in human ES tumors, a ﬁnding also observed in breast can-
cer cells grown in 3D cultures [168]. Taken together, an engineered ES
tumor model reliant upon electrospun PCL ﬁbers scaffolds appears to
adequatelymimic themorphology, growth kinetics, and protein expres-
sion proﬁle of human tumors. Ultimately, one of the most important
questions to be resolved iswhether the 3Dmodel shares enough ﬁdelity
with its human counterpart to advocate its use in a preclinical high-
throughput drug-testing platform.
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Though the aforementioned experience culturing ES cells as spher-
oids or 3D scaffolds was limited to growth upon unmodiﬁed surfaces,
they serve to lay the groundwork in our understanding of how ES and
other cancerous cell types intrinsically interact with a spatially complex
biologically inert microenvironment. As these models fail to adequately
represent the richer complexity of human biology of proven importance
for cancer growth, invasion, andmetastasis the next challengewould be
to add back key components of the ECM to inert scaffolds and/or employ
decellularized biological tissues devoid of cells to isolate the speciﬁc ef-
fects induced by the residual ECM [136,169–175].
With respect to the former approach, in which biological ECM sup-
plements the tissue-engineered microenvironment, both Matrigel (a
poorly deﬁned gelatinous complex of proteins derived from
Engelbreth–Holm–Swarm (EHS) mouse sarcoma cells) and peptides
rich in Arginine–Glycine–Aspartic acid (RGD) motifs have been widely
reported to affect cell behavior and alter cell self-organization. Matrigel,
for example, can induce interconnected capillary-like networks of endo-
thelial cells thatwould not otherwise form inmonolayer culture and, in-
terestingly, ES-secreted VEGF165 enhances this process. As a speciﬁc
recognition site of integrins for their respective ligands, RGD is a ubiqui-
tous biomimetic peptide presentwithin plasma and ECM that is capable
of promoting cell motility and stimulating adhesion between tumor
cells and their supporting stromal cells and/or ECM. A number of excel-
lent publications exist that expand on the important roles Matrigel and
RGD motifs play in the tumor microenvironment [176–178].
With respect to ES and the other sarcoma subtypes, little is known
about the ex vivo cell-derived ECM and this inquiry remains a
burgeoning avenue of investigation. Several reports have described
the composition of ﬁbronectin, laminin, and collagen in ES cell lines
and/or clinical samples [179–181]. Vijayakumar et al., for example,
demonstrated low levels of beta-catenin (Wnt-pathway) in monolayer
ES cultures [182]. Others have reported that ECM/scaffold-related ef-
fects of the E-cadherin expression, with high expression by ES cells
grown within scaffolds, intermediate expression in spheroids, and low
expression in monolayer cultures [53]. Since E-cadherin-dependent
co-expression of ErbB4 in ES spheroids appears to up regulate theFig. 4. Scanning electron micrographs of PCL microﬁber scaffolds, (A) before cell seeding,
(B) after 2 days in static ES cell culture, and (C&D) after 24 days in static ES cell culture.
After 24days of static culture, ES cells exhibit signiﬁcant 3D cell–cell and cell–matrix contacts.
AB
Fig. 5. IHC staining of human ES tumor for VE-Cadherin under low- (A) and high-power
(B) magniﬁcation conﬁrming the coexistence of EC.
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sistance to anoikis and cytotoxic chemotherapy, it is intriguingwhether
a similar phenomenon is occurring in our 3D PCL-based scaffold archi-
tecture [183]. ECM deposition by human tumors can clearly induce an
adverse autocrine effect that promotes malignant cell invasion and
metastasis. Thus, the ability to mimic this tumorigenic regulatory loop
in ex vivo models of the tumor microenvironment may advance our
understanding of dynamic interplay that occurs between tumors and
their surrounding ECM, and potentially aid in the development of
drugs that target the tumor microenvironment [184,185].
Accurately isolating the effects of tumor-associated ECM from the
effects of surrounding stromal cells would be nearly impossible using
conventional 2D or xenograft preclinical models but can readily be
accomplished in tissue-engineered systems. Decellularized connective
tissues, usually obtained after perfusion with detergents, provide an
example of this approach and have recently gained in popularity for
cancer research given their unique ability to evaluate the oncogenic
effects of naturally derived ECM. The effects of bone-speciﬁc ECM has
been reported using decellularized PCL scaffolds that had originally
supported osteogenic cells [186], and direct chemical conjugation
of speciﬁc ECM proteins or proteoglycans to the surface of PCL ﬁbers
can allow controlled release of high-afﬁnity ligands (e.g., heparin
sulfate binding growth factors or cytokines) from the 3D scaffolds
[187,188].
4. Applications for cancer biology and preclinical drug testing
Though a longstanding goal of tissue engineering has been to fabri-
cate artiﬁcial tissues and organs capable of replacing diseased human
tissues, as of yet, there are still no FDA approved substitutes for major
organ systems. Nevertheless, considerable progress has been made
and many of the principles used to further that aim have been adapted
tomodel the human tumor niche. As discussed previously, our laborato-
ry has had the greatest success using electrospun scaffolds composed of
PCL, a resorbable aliphatic synthetic polymer that has been extensively
used by the tissue engineering and the biomedical community. It offers
a number of highly desirable properties, including the following:
(a) lacks intrinsic biological or biochemical activity, (b) is inexpensive
(c) is readily manipulated to produce ﬁbers of precise diameter,
(d) has superior rheological and viscoelastic attributes, (d) is considered
safe by the FDA, and (e) exhibits very slow in vivo degradation, which
can be ﬁnely tuned using copolymer blending to achieve the intended
biological effect. Both normal and cancerous cells adhere to PCL, and
when electrospun, non-woven mats of 10 μm diameter PCL ﬁbers can
be made to resemble the native ECM [189], including physiological
bone trabeculae and thebonyES tumor niche [54]. Perhaps themost im-
portant for our applications,micrometer size electrospun PCLﬁbers pro-
vide the requisite porosity to enable cell inﬁltration and are compatible
withﬂowperfusion bioreactors [190–195]. As speciﬁcally used tomodel
ES, the 3D pattern of electrospun ﬁbers appears to induce pronounced
changes in ES cell morphology, growth kinetics, and expression of
cancer-related pathways, which in turn, promotes chemosensitivity
patternsmore closely observed in xenografts and human tumors. Excel-
lent reviews exist that highlight the broad applicability of PCL for tissue
engineering, drug delivery, and medical devices [196,197].
4.1. Morphologic characterization of 3D tumor models
Despite the aforementioned beneﬁts, PCL 3D scaffolds also have
their drawbacks. Cells grown within 3D scaffolds can be difﬁcult to dis-
lodge; isolation of RNA, DNA, and protein can be difﬁcult; and lowmelt-
ing temperatures (60 °C for PCL) preclude standard tissue embedding
with parafﬁn. And as a class, polymeric 3D scaffolds are usually opaque
and poorly amenable to routine light microscopy even when polysty-
rene or other clear substrates are used. Naturally, this poses a major
challenge to monitoring cell morphology and proliferation in realtime, which in turn, impairs ones ability to continuously monitor the
health and viability of cultured cells. This disadvantage can bemitigated
to someextent by simply culturing ES cells onmultiple scaffolds concur-
rently then sectioning some at various time intervals. Once sectioned,
they can be evaluated by scanning electronmicroscopy (SEM) or immu-
nohistochemistry (IHC). Flow cytometry (FC) can be used to comple-
ment SEM and IHC analyses but, as with those techniques, interrupts
the experiment in the course of completing the analysis (Fig. 5). Since
the cells are removed from the scaffolds prior to analysis, one cannot
evaluate the spatial interrelationship of the cell–cell interaction.
Theoretically, the cells extracted from scaffolds for FC analysis could
be handled aseptically and replaced within a new scaffold but, in
practice, this is uncommon and only performed in the rare case where
a distinct subset of cancer cells is required.4.2. 3D models used to assess chemosensitivity
Though cell culture monolayers will continue to offer value to the
cancer research community, particularly when used in high-
throughput drug screening programs, the data resulting from their use
canprove unreliable, orworse, contradictory towhat one eventually ob-
serves when tested in xenografts or human tumors. Emblematic of this
limitation, the NCI-60 (a well characterized set of 60 diverse cancer cell
lines) has been extensively used to identify novel antineoplastic agents
but poorly predicts whether any single drug will be effective in treating
speciﬁc cancer type.While this incongruencemay, to some extent, stem
from artiﬁcially high cell division rates that overestimate the beneﬁt of
cytotoxic chemotherapies, marked phenotypic variation between
monolayer and 3D culture systems (and human tumors) provides an-
other explanation [53,54]. In support of this hypothesis, the proteomic
signature of human tumor spheroids and 3D scaffold models can be
readily distinguished from equivalent cells maintained in monolayer
culture. This appears to hold true for ES as well, as cells grown within
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mate the protein expression pattern of human tumors than do cell
monolayer cells [53,54,80,86,90].
Drug companies have taken note and many have added 3D cell cul-
ture models to their preclinical testing pipeline while continuing to rely
extensively upon xenograft testing to determine a drug candidate's
activity, toxicity, and pharmacokinetic proﬁle (i.e., absorption, distribu-
tion, metabolism, and elimination). As biologically targeted cancer
therapies continue to garner a large share of the drug marketplace,
one can anticipate an even greater need for preclinical culture models
that more accurately replicate the signaling pathways responsible for
cancer progression.
4.3. 3D models amenable to high throughput drug screening
Toward that end, a number of techniques—such as hanging drops,
micro-etched nano-cultures using NCP, and liquid overlay methods—
are among just a handful capable of producing uniform ES spheroids
amenable to high throughput drug screens (HTS). Although there is
no consensus on what qualiﬁes as a HTS, robotic automation of plate
handling and drug administration hasmade it easier than ever to screen
hundreds, if not thousands, of compounds perweek in commercial scale
laboratories. Such mechanization has also permitted complementary
methods, such as RNA interference, that can be used to identify putative
mechanisms of resistance. Our laboratory, as an example, has per-
formed spheroid-based HTS in 384-well micro-etched NCP to identify
several likely mechanisms by which ES evades mTOR inhibitor activity.
As expected, the use of HTS is critically dependent biometric
measurement of drug effects, and at least four main types of assays
have emerged for that purpose: (i) assays that measure morphological
changes in spheroid volume using automated or semi-automated
imaging, (ii) cytotoxicity and cell viability assays that measure cell
membrane integrity or intracellular metabolic activity under robust
detection readouts (e.g., absorption, luminescence, and ﬂuorescence),
(iii) apoptosis assays that reliably assess drug-induced apoptosis and
cell death, and (iv) gene expression assays that evaluate speciﬁc
phenomena like metastatic potential.
5. Future directions
As discussed in the Introduction, 3D ES models come in two major
varieties: cell aggregates capable of intrinsic self-organization
(i.e., tumor spheroids) and multidimensional cell aggregates that grow
within artiﬁcial substrates. The latter implementation should be espe-
cially well suited to answer scientiﬁc questions that relate heterotypic
cell–cell interactions and provide a unique opportunity to explore auto-
crine or paracrine effects upon oncogenesis, angiogenesis, metastasis,
and immunomodulation. Advances in biomaterials, such as scaffolds
and gels, have provided the essential building blocks necessary to
recreate selected aspects of the tumor microenvironment.
5.1. Heterotypic co-cultures
Though the ES cells grow asmonotonous sheets that lack features of
intrinsic self-organization (ductal structures in breast cancer, for exam-
ple), microscopic review of ES tumors ﬁnds other connective tissue cells
(ﬁbroblasts and adipocytes), inﬂammatory cells (lymphocytes, macro-
phages, and natural killer cells), and vascular cells, including pericytes
and endothelial cells (Fig. 5). Together with the associated ECM, the
tumormicroenvironment has been identiﬁed as amajor factor inﬂuenc-
ing tumor survival, growth, invasion, metastasis, and response to che-
motherapy [50,198–202]. Because these heterotypic cell interactions,
and surrounding ECM, can be selectively introduced into the tissue-
engineered 3D scaffolds they serve as ideal platform to study the dy-
namic effects of cell–cell and cell–ECM contact.5.1.1. ES-MSC co-culture for modeling Ewing's sarcoma
As reported earlier, a wealth of information suggests that ES origi-
nates from a single primitive MSC that acquired a tumorigenic
EWSR1/FLI1 translocation, and as such, this cell type has been exten-
sively used to elucidate the genetic perturbations that promote
malignant transformation [17,20,21,198–201,203–206]. Equally well-
documented, ectopic expression of the resulting EWS/FLI1 fusion
protein in permissiveMSCs is necessary but insufﬁcient of inducingma-
lignant transformation without co-expression of other dysregulated
proteins [207].
Given these facts, and taking into account the profound effects that
the cell culture microenvironment has upon the collection, puriﬁcation,
and differentiation of humanMSC, confusing or frankly incorrect scien-
tiﬁc conclusions could be reached by studying EWSR1-FLI1-transfected
hMSCs in monolayer cultures devoid of the relevant 3D architecture,
ECM, growth factors, and support cells [208]. Our own experience, albeit
starting from pre-established ES cell lines, demonstrated the simple
transition from monolayer culture to biologically inert PCL scaffolds in-
duced salient changes in the very same proteins (IGF-1, for example)
that are required for malignant transformation. This would suggest
that, at the very least, one should consider a more physiological
bone tumor niche, whether natural or processed, in prospectively
deciphering the critical interchange that exists between EWS-FLI and
its coconspirators.5.1.2. ES-EC co-culture and angiogenesis modeling
Endothelial cells are indispensible to the healthy formation of rich
vascular networks, which occurs through a process of angiogenesis,
vasculogenesis, and/or tumor cell vascular mimicry [209]. To mimic
those processes within a synthetic tissue grown in the laboratory, and
thereby improve tissue viability and function, ECs have been used in a
wide range of tissue-engineering applications. Unexpectedly, even be-
fore a mature vascular network is formed, ECs can affect co-cultured
cells and inﬂuence the surrounding microenvironment. When mixed
with MSCs, for example, ECs enhance osteogenic matrix production
within 3D PCL scaffolds [210,211].
As expected, EC-mediated angiogenesis/vasculogenesis also plays an
incredibly important role in tumorigenesis. As what occurred for other
tumors, ES tumors have been shown to possess the capacity to regulate
their own survival and appear to do so by secreting soluble vascular
endothelial growth factor (VEGF) that secondarily recruits bone
marrow derived cells, pericytes, and endothelial cells into ES tumors
[198–201]. A similar phenomenon occurs in preclinical models of ES,
as co-culture of human EC and ES cells within an ECM gel can induce
vascularized endothelial tubes [50]. Indirectly tied to VEGF expression,
the insulin-like growth factor-1 receptor (IGF-1R) has also been
implicated in the modulation of angiogenesis and vasculogenesis [212]
and dual targeting of IGF-1R and its ligand elicits anti-angiogenic
effects [50].
To our knowledge, ECs have not been used in co-culture within ES
cells within 3D scaffolds but this system would be expected to provide
a unique opportunity to decipher the two-way feedback that exits be-
tween these cell types. A step in this direction, human MSCs, which
could serve as a precursor for ES, and human umbilical vein endothelial
cells (HUVECs) were co-cultured in 3D PCL-scaffolds under conditions
of ﬂow perfusion. Superior proliferation of both cell lines was achieved
and the spatial distribution was more uniform throughout 3D-PCL scaf-
folds [213]. Since VEGF secretion by human ES tumors has been shown
to encourage CD38− primitive MSCs to migrate from the bonemarrow
to the tumor, where they differentiate into ECs and/or pericytes capable
of angiogenesis and vasculogenesis [198–201], it would be intriguing to
know whether a similar effect could be replicated within a tissue-
engineered ES model. If achievable, one could directly measure the ef-
fect of ES-produced IGF-1 andVEGF ligands upon ex vivo vasculogenesis
and possibly use this novel model to develop and test antineoplastic
165S.-E. Lamhamedi-Cherradi et al. / Advanced Drug Delivery Reviews 79–80 (2014) 155–171agents that intercede with the ES's ability to self-regulate their
microenvironment.
5.1.3. Use of the 3D ES model to study immune-mediated therapy
Immune cells, including tumor-inﬁltrating lymphocytes, macro-
phages, dendritic cells and NK cells, can either maintain or suppress
ES tumor growth depending upon the context in which they interact
[214–219]. And though beyond the scope of this review, a handful of bi-
ologically targeted therapies designed to stimulate the immune system
—either directly or by down-regulating immune checkpoints such
as programmed cell death 1 (PD1) or cytotoxic T-lymphocyte antigen
4 (CTLA-4)—have generated incredible acclaim for their remarkable
antineoplastic activity in appropriately selected patients. While it
remains to be determined if those promising results would hold up
when eventually applied to patients suffering from ES, this has become
a robust area of research.
NK cells, expanded in vitro, have been shown to provoke signiﬁcant
anti-tumor effects in mice engrafted with ES cells, and in rare instances
completely eradicated the disease [216]. Activated NK cells, more so
than resting ones, have also shown immunoreactivity in ES tumors
[217]. Yet, the regulation of NK cell cytolytic activity is complex and
induces both activating and inhibitory receptors as well as induced
tolerance to speciﬁc self-receptors. A reﬁned understanding of these
signals could empower novel therapies for ES.
As a platform for investigating the role of immune cells in sup-
pressing ES tumor growth, one could envision co-culturing ES cells
with the speciﬁc immune cell of interest (e.g. NK cells) within a
PCL based tissue-engineered scaffold. Though the full complexity of
the human and/or mouse immune system can't be modeled in its en-
tirety ex vivo, the exceptional ﬂexibility of the system and greater
control of the ES–immune cell interactions may outweigh some of
its limitations. There are a number of approaches one might take:
(i) utilization of allogenic killer immunoglobulin-like receptor
(KIR) incompatible NK cells, (ii) blockade of KIR with mAb, (iii)
transfection of NK cells to express tumor reactive T-cell receptors
(TCRs) or chimeric antigen receptors (CARs), and (iv) sensitization
of ES tumor (or cells) to NK cell killing.
The successful activation of Cytotoxic T-cells (CTL) from healthy
human peripheral blood mononuclear cells (PBMC), using a modiﬁed
EWS-FLI1 peptide, and potent killing of cells bearing the EWS-FLI1
translocation provides renewed hope in developing T-cell mediated
immunotherapy for ES treatment [220].
5.2. Multi-organ tissue-engineered systems to study metastasis
Most ES-related deaths occur when malignant cells have metasta-
sized to the lung, grown within that location, and developed de novo
or acquired resistance to chemotherapy. Although primary thoracic ES
tumors (i.e. Askin tumors) do occur and can spread to adjacent lung
tissue by direct extension, the vast majority of ES cells canmore reason-
ably be expected to transit to the lung after ﬁrst leaving the primary site
(e.g. bone tissue or less common extraskeletal tissues), entering the
circulatory system, and adhering to pulmonary endothelium (Fig. 6).
Despite the deterministic nature of these steps, little is known about
the cellular, biomolecular and environmental factors that explain the
predictable nature in which ES cells appear in the lung, at least
microscopically, very early in the disease course. For this reason, all
patients diagnosed with ES are universally provided chemotherapy
with the dual goals of shrinking the macroscopic, clinically detectable
tumors and eradicating micrometastatic deposits that are assumed to
exist within the lung even when small tumors are effectively treated
by surgery or radiation.
Though ES cells intrinsically harbor the capacity to metastasize and
can gain even greater metastatic potential by acquiring genetic aberra-
tions, the surrounding stromal cells and ECM are critical partners that
inﬂuence this continuum from the bone to the lung. In teasing apartthe metastatic triggers intrinsic to the cancer cell from extrinsic ones
ascribed to microenvironmental effects highlighted in Fig. 1, tissue-
engineered tumormodels of the bone and pulmonary sites afford scien-
tists previously unimaginable experimental control to adjust biome-
chanical forces, the signaling milieu, and metabolic stresses. Though
not previously used to study ES metastasis, a number of tissue-
engineered and/or ex vivo regenerated lung tissue models have been
shown tomimic functional lung, and one could envision a closed system
that uses microﬂuidic channels link tissue-engineered bone and lung
tissues together in a way that mimics the complete pattern of hematog-
enous spread. As illustrated in Fig. 6, the 3D scaffolds that our group and
others have reported upon can mimic the bone tumor niche, and both
lung-on-a-chip [221] and decellularized lung models [222–227] appear
to be conducive to the adhesion and growth of cancer cells. Thus far,
only non-small cell lung cancers (NSCLC) have been implanted within
these tissue-engineered lung models, however unpublished reports by
Dr. Min Kim et al. (personal communication) indicate ES cells readily
form distinct pulmonary nodules when placed within decellularized
rat lungs that are maintained under conditions of ﬂow perfusion previ-
ously used to grow NSCLC [228]. As a ﬁnal piece of the puzzle, Ingber
et al. demonstrated that miniaturized tissue-engineered organs grown
ex vivo can be linked in series to mimic the physiological vascular
communications that exist in the human body, so it stands to reason
that similar methods could be adapted to join synthesized bone and
lung together as an innovative system to study ES metastasis.
Though considerable effort will surely be required to move beyond
theoretical possibilities, and recognizing that even the best ex vivo sys-
tems lack important factors inherent in living organisms, multi-organ
tissue-engineered systems present an enticing chance to interrogate,
and hopefully thwart, the critical factors that make the lung microenvi-
ronment such a hospitable place for ES and other sarcoma subtypes to
grow.5.3. Personalized therapy
Given the relative rarity of ES and further molecular sub-
classiﬁcation of patients by their tumor's translocation type and
proteomic signature [22–31,229], it is impossible to adequately test all
drugs or rational drug combinations in each patient subset [230]. A
partial solution to this problem has been to extensively proﬁle each
patient's tumor to identify dysregulated proteomic pathways, genomic
mutations, or other ‘-omic’ aberrations responsible for tumorigenesis
and to isolate mechanisms of de novo and acquired drug resistance
[231–233]. This approach, however, must eventually be validated
using drug candidates in xenografts or cell lines that truthfully mimic
the human tumors from which they derive. Though simple in theory,
this latter step has remained a challenge in practice, as pre-established
xenografts and/or cell lines devolve over time and eventually lose the
phenotypic traits originally present within the respective tumors from
which they'd been taken.
In an effort to maintain the intimate link between clinical tumor
samples and thederived xenografts and/or cell lines, academic laborato-
ries and pharmaceutical companies alike havemademajor investments
establishing primary cell lines and PDX frompatients that have carefully
annotated clinical response data available. To ensure that PDXmaintain
a high correlation with the source tumor, early generation explants are
used before they lose the surrounding human-derived ECM, considered
essential for maintaining ﬁdelity with their human counterparts. Simi-
larly, 3D primary cell culture models are being developed to mirror
the native ECM and architectural structures present within human
ES tumors in the hopes that those elements will preserve, or at
least prolong, a differentiated phenotype that is truly representative
of the original ES tumor. Admittedly, the scientiﬁc community has
much less experience growing primary cell lines as spheroids and
very few laboratories have the specialized expertise necessary to
Fig. 6.Bioengineeredmodels thatmimic ESmicroenvironment at the primary, hematogenous and secondary sites. (A) Bioengineered preclinicalmodels of ES interactingwith osseous-like
3D scaffold (B) or synthetic vasculature (C). (D) Vascular system by which ES disseminates to lung. (E) Lung metastases modeled lung. (F) Lung-on-chip or (G) Decellularized lung.
Abbreviations: CTC, circulating tumor cells; EC, endothelial cell; ECM, extracellular matrix; MSC, mesenchymal stem cell; and WBC, white blood cell.
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microenvironments.
The limited 3D tissue-engineered tumor models that do exist lack
standardization and may need to incorporate subtle changes in the fab-
ricated scaffolds to enable primary cell culture of different cancer types.
Thus, a one-size-ﬁts-all tissue-engineered approach for all cancer types
is unlikely and wouldn't necessarily be expected given the vast differ-
ences sarcomas and carcinomas have in their proclivity for certain
metastatic sites. Sarcomas (including ES), for example, spread more
commonly to the lungs and bone, whereas carcinomas usually migrate
ﬁrst to lymph nodes before metastasizing elsewhere. Given this afﬁnity
for one tissue type over another, one would contend that a principal
advantage tissue-engineered 3D scaffolds have over spheroids and
monolayer cultures are their capacity for customization to meet the
unique microenvironmental needs of the cancer type of interest. Our
laboratory has just begun the time-intensive task of culturing primary
ES cells within 3D PCL scaffolds and continues to optimize the tech-
niques required to maintain cell viability within an ex vivo tissue-
engineered tumor niche (Supplemental Fig. 1). The next step will be
to correlate the expression proﬁles of clinical samples with their paired
PDX and cell-embedded 3D scaffolds to ensure that they successfully
recapitulate the human ES tumors. Subsequently, we anticipate using
biomimetic ES tumor models to methodically evaluate biologically
targeted therapies in advance of early phase human clinical trials of
the most promising drug candidates. Simultaneously, one expects that
the preclinical ES models will shed new light of drug resistance mecha-
nisms and promote the use of innovative drug combinations that would
not have been apparent frommore primitivemonolayer culturemodels
that lack in vivo-like signaling cascades.6. Conclusion and perspectives
Complex 3Dmodels of human cancer (including ES) are just emerg-
ing in academic labs throughout the country and are anticipated to
revolutionize the study of the tumor microenvironment. By providing
new tools to manipulate the ex vivo tumor niche of both the primary
and metastatic sites in ways not currently possible using murine
models, tissue-engineered cancer models could serve as an ideal plat-
form to test new cancer therapeutics. Challenges remain, particularly
in scaling up these systems for HTS and adapting them for ubiquitous
use by the cancer research community, but these hurdles are not
insurmountable.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.addr.2014.07.012.
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